Clinical trial · Interventional
LIPT - Liraglutide in Polycystic Ovary Syndrome
A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease. The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS. 70 women will be included in af RCT. Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiovascular Disease | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Liraglutide for 26 weeks | Drug | — | UNRESOLVED |
| placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Active
- description
- Liraglutide s.c. 1,8mg daily for 26 weeks
- interventionNames
- Drug: Liraglutide for 26 weeks
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo s.c. daily for 26 weeks
- interventionNames
- Drug: placebo
Primary outcomes (1)
- measure
- Change in Endogenous Thrombin Potential (ETP)
- timeFrame
- at time 0 and 26 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * PCOS * \>18 years * premenopausal * BMI \>25 og 25 and thereunder + insulin resistent Exclusion Criteria (including): * actualt or intended pregnancy * inadeqvat contraception * hormonal contraception within 6 weeks * metfoomin, GLP-1-analog or DPP IV inhibitor within 3 months * medications affectiv hemostatic mechanisme * diabetes or other severe comorbidity * familar MEN * ...
References
Publications (1)
- DERIVEDFrossing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, Skouby SO, Faber J. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes Obes Metab. 2018 Jan;20(1):215-218. doi: 10.1111/dom.13053. Epub 2017 Aug 11. PMID 28681988